☆ 4.7 Article

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Risk Compensation and COVID-19 Vaccines

Brit Trogen et al.

ANNALS OF INTERNAL MEDICINE (2021)

添加到收藏夹

Review Infectious Diseases

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

Susanne H. Hodgson et al.

Summary: The development of a vaccine for the novel coronavirus is crucial to prevent the spread of the pandemic and reduce disease mortality. The efficacy endpoint is protection against severe disease and death, but evaluating this in phase 3 clinical trials poses challenges.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Neutralizing Activity of BNT162b2-Elicited Serum

Yang Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

Victoria Jane Hall et al.

Summary: The study aimed to determine the factors associated with vaccine coverage for two COVID-19 vaccines in the UK and to document the vaccine effectiveness of the BNT162b2 mRNA vaccine among healthcare workers. Results showed that the vaccine can prevent both symptomatic and asymptomatic infections in working-age adults, with a vaccine effectiveness of 70% after the first dose and 85% after the second dose.

LANCET (2021)

添加到收藏夹

Letter Medicine, General & Internal

New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications

Salim S. Abdool Karim et al.

Summary: The emergence of SARS-CoV-2 variants, including B.1.1.7 (VOC-202012/01), 501Y.V2 (B.1.351), and P.1 (B.1.1.28.1), has raised concerns about worsening Covid-19 and potential escape from vaccine-induced immunity.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout

相关参考文献

Risk Compensation and COVID-19 Vaccines

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Neutralizing Activity of BNT162b2-Elicited Serum

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications

导出引文

分享论文